To test this hypothesis, we evaluated the effect of GSDMB2 expression on breast cancer generation and progression in concert with two different strong oncogenes, HER2/NEU (Guy et al., 1992b) or the PyMT (Guy et al., 1992a). The gene discussed is ERBB2; the disease is breast cancer.